Key Highlights
- Avacta Group PLC (LSE:AVCT), the AIM-quoted oncology developer, is in focus on 16 October 2026 following a £12.5m placing and subscription priced at 68p per share.
- Management hosted a live interim results investor presentation on 15 October 2026, the day before the focus date.
- Two posters are scheduled for ESMO 2026 in Madrid on 26 October, covering AVA6000 survival outcomes and the AVA6103 FOCUS-01 trial design.
- Cash runway has been extended into the second quarter of 2027, while the company flags a material going concern uncertainty in its interim accounts.
- First clinical efficacy data from AVA6103 are expected in the first half of 2027, with AVA6207 candidate news targeted for the fourth quarter of 2026.
Why Avacta Is in Focus on 16 October 2026
Avacta Group PLC (LSE:AVCT) heads into late October with a busy catalyst calendar, drawing attention from AIM investors on 16 October 2026. The company, which trades on the London Stock Exchange AIM market within the FTSE AIM All-Share universe, has just completed a fundraise, presented its half-year numbers and confirmed it will appear at a major oncology congress.
The live interim results presentation, led by Chief Executive Christina Coughlin and Chief Financial Officer Brian Hahn, took place at 16:00 BST on 15 October 2026, with AVA6103 and the FOCUS-01 trial expected to dominate questions. The market is now looking ahead to the European Society for Medical Oncology congress, which runs from 23 to 27 October 2026.
The £12.5m Placing and Subscription
On 6 October 2026 Avacta confirmed gross proceeds of £12.5m through a placing and subscription of 18,382,353 new shares at 68p each. The price represented a discount of about 5.6 per cent to the 72p closing price on 29 September 2026, the last trading day before the company opened its capital access window. The new shares equal roughly 3.9 per cent of the existing share capital, and the enlarged share count after admission stands at 489,712,861 ordinary shares.
Four directors subscribed for 970,587 shares, worth about £660,000, led by Richard Hughes with £500,000. Avacta shares resumed normal trading on AIM on 6 October after a suspension that began on 30 September.
The company says the fresh money extends its cash runway from early first quarter 2027 into the second quarter of 2027. Commentary around the deal indicated that around £2.5m is earmarked for a cash repayment on a quarterly convertible bond instalment due on 20 October 2026, with the balance supporting the AVA6103, AVA6000 and AVA6207 programmes and general working capital.
Interim Results: The Numbers Behind the Pipeline
The interim results for the six months to 30 June 2026, published on 30 September, showed continuing revenue of £0.06m, unchanged on the prior year. Research costs climbed to £9.69m from £7.20m, while the operating loss from continuing operations eased slightly to £13.91m from £14.18m. Loss after tax from continuing operations widened to £19.02m from £16.13m, and basic loss per share was 4.23p.
Cash stood at £20.27m on 30 June 2026 and £10.59m on 31 August 2026, before the October raise. The convertible bond outstanding loan was £12.00m at 30 September. The board has stated that a material uncertainty exists regarding going concern.
Pipeline Progress: AVA6103, AVA6000 and AVA6207
Avacta's pre|CISION platform targets Fibroblast Activation Protein to release chemotherapy payloads inside tumours. AVA6103, a controlled-release exatecan conjugate, received FDA IND clearance in January 2026 and treated its first patient in March. Phase 1a data show a clean safety profile through the first three dose levels, including a payload dose 50 per cent above the conventional exatecan maximum tolerated dose at dose level three. These are safety and mechanism readouts rather than efficacy data, which are expected in the first half of 2027.
AVA6000, also known as faridoxorubicin, continues in Phase 1b, and the company intends to advance it through a partnership. AVA6207, a dual-payload programme, is due to reach clinical candidate selection in the fourth quarter of 2026 ahead of IND-enabling studies.
ESMO 2026: The Next Visible Catalyst
At ESMO 2026 in Madrid, Avacta will present poster 1549P on 26 October from 12:00 to 12:45 CET, covering progression-free survival results for salivary gland cancer patients in the AVA6000 Phase 1a/1b trial, along with FAPI-PET imaging from the same expansion cohort. A second e-poster, 1134eTiP, will set out the FOCUS-01 trial design for AVA6103 and updated preclinical data across cervical, HR-positive breast, small cell lung, gastric, colorectal and pancreatic cancers.
Sector Context
Peptide drug conjugates sit within the wider XDC category, where sentiment for AIM biotech names such as Avacta Group PLC (LSE:AVCT) hinges on clinical data and partnering.
What Investors Are Watching Next
Near-term attention centres on the convertible bond instalment due on 20 October, the ESMO posters on 26 October, AVA6207 candidate selection in the fourth quarter and any progress on partnering talks. Further out, the first AVA6103 efficacy data in the first half of 2027 are expected to be the defining event for the LSE:AVCT investment case.
Key Risks
Avacta remains a clinical-stage company with minimal revenue, a convertible bond and a stated going concern uncertainty. The runway into the second quarter of 2027 is limited, meaning further funding or partnering may be required. Early clinical results may not be repeated in later trials, and AIM shares can be volatile.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...